Ligand Pharmaceuticals (LGND) Non Operating Income (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Non Operating Income of -$41.6 million for Q1 2026, down 196.95% sequentially from $42.9 million in Q4 2025, and down 198.1% YoY from $42.4 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Non Operating Income (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Non Operating Income for 17 years, with the latest figure at -$41.6 million in Q1 2026.
- Quarterly Non Operating Income fell 198.1% year-over-year to -$41.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $90.3 million (up 190.93% YoY) and the FY2025 annual result came in at $118.0 million, up 369.5% from the prior year.
- Non Operating Income fell to -$41.6 million in Q1 2026 per LGND's latest filing, from $42.9 million in the prior quarter.
- Over five years, Non Operating Income peaked at $110.5 million in Q1 2024 and troughed at -$46.3 million in Q2 2024.
- A 5-year average of $10.9 million and a median of $13000.0 in 2022 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 515500.0% in 2023, down 117192.31% in 2023.
- Over 5 years, Non Operating Income stood at $44.2 million in 2022, then slumped by 53.76% to $20.5 million in 2023, then sank by 244.53% to -$29.6 million in 2024, then soared by 245.24% to $42.9 million in 2025, then slumped by 196.95% to -$41.6 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$41.6 million, $42.9 million, and $86.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 55.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.71 Mn |
| Mar 31, 2026 | -41.63 Mn |
| Dec 31, 2025 | 42.94 Mn |
| Sep 30, 2025 | 86.21 Mn |
| Jun 30, 2025 | 2.78 Mn |
| Mar 31, 2025 | -13.96 Mn |
| Dec 31, 2024 | -29.56 Mn |
| Sep 30, 2024 | -9.48 Mn |
| Jun 30, 2024 | -46.29 Mn |
| Mar 31, 2024 | 110.46 Mn |
| Dec 31, 2023 | 20.46 Mn |
| Sep 30, 2023 | -15.22 Mn |
| Jun 30, 2023 | 5.15 Mn |
| Mar 31, 2023 | 41.33 Mn |
| Dec 31, 2022 | 44.24 Mn |
| Sep 30, 2022 | 13,000.00 |
| Jun 30, 2022 | -1,000.00 |
| Mar 31, 2022 | -11.28 Mn |
| Dec 31, 2021 | -19.81 Mn |
| Sep 30, 2021 | -447,000.00 |